A Study on Budesonide/ Formoterol vs. Fluticasone/ Salmeterol Inhaled Combination in Moderate to Severe Asthma
Journal Title: Journal of Pharmaceutical and Biomedical Sciences - Year 2014, Vol 6, Issue 2
Abstract
Background and Objectives The addition of an inhaled long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS) gives optimal control of asthma in most patients. The LABA salmeterol xinafoate (salmeterol) with inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and formoterol with budesonide are available as a combination product pMDI in a single aerosol inhaler. This study compared the efficacy and safety of commercially available salmeterol/fluticasone with formeterol/budesonide. Materials and Methods Patients aged >12 years inclusive of either sex (N = 40) with persistent asthma as defined by NHLBI for >6 months prior to screening were included in the study. After a screening phase (1 week), eligible patients were enrolled in the study with 2 weeks run-in period. Eligible patients were randomized to receive either of the two treatment groups [HFA-propelled pMDI salmeterol/fluticasone (50/100 mcg) or HFApropelled formoterol/budesonide (6/100 mcg) pMDI] in a ratio of 1:1 for the 12-week treatment period. The primary objective was to demonstrate non-inferiority of salmeterol/ fluticasone vs. formoterol/budesonide, measured by mean pre-dose forced expiratory volume in the first second (FEV1), at week 12. Results This study provides evidence for the primary efficacy endpoint that salmeterol/ fluticasone was statistically as well as clinically non-inferior to formoterol/budesonide in the treatment of patients with persistent asthma. This was supported by secondary endpoints which demonstrate that salmeterol/fluticasone appeared to be comparable to formoterol/budesonide in terms of efficacy for the secondary efficacy endpoints (morning PEFR, evening PEFR, diurnal variability of PEFR, daytime and night-time asthma symptoms score, average need for short-acting β2-agonists, proportion of patients that required rescue medication, patients with nocturnal asthma, patients without asthma symptoms of score 0 and average number of days without asthma symptoms of score 0). Salmeterol/fluticasone was safe and well tolerated; and safety profile is comparable to comparator formoterol/budesonide. Conclusion The results of this study demonstrate that HFA formulations of salmeterol/ fluticasone and formoterol/budesonide are clinically interchangeable. Overall, the study indicates that HFA-propelled salmeterol/fluticasone (50/100 mcg) pMDI was safe, well tolerated and non-inferior in efficacy compared to HFA-propelled formoterol/budesonide (6/100 mcg) pMDI.
Authors and Affiliations
Sarat Kumar Behera
Keywords
Related Articles
- EP ID EP183981
- DOI -
- Views 115
- Downloads 0
A Rare Case of Porencephaly Presented with Status Epilepticus to Emergency Medicine
Porencephaly is an extremely rare disorder of the central nervous system involving cysts or cavities in the cerebral hemispheres. Here is a case of porencephaly who presented to the emergency department with status epile...
Evaluation of Efficacy of Tongue Cleaning With and Without Aloe Vera Oral Gel in the Management of Halitosis
Halitosis is a common problem in the general population and has a significant impact on social and psychological aspect. Research has found a correlation between bacterial load of the tongue and halitosis. Therefore, tre...
Myelofibrosis Case in a Child
Complexity myelofibrosis diagnosis at an early stage is that it takes place under other conditions mask: anaemia, abdominal pain, enlarged liver and spleen. This article describes a case of myelofibrosis in a child, when...
Cavity Depth vs Cavity Width in Generating Stress Patterns: A FEA Study
Indirect tooth restoration involves customized tooth replacements in the form of crowns, onlays, or inlays. The preparation design for an indirect restoration must maintain a balance between preserving the tooth structur...
Neoplasms Arising from the Salivary Gland: A Comprehensive Review
The main aim of current probe is to formulate and evaluate transfersomal gel for effective transdermal delivery of Tramadol Hcl. It was investigated by encapsulating the drug in various formulations which composed of var...